Close menu




September 10th, 2021 | 11:16 CEST

GameStop, wallstreet:online, Nikola - It goes on blithely

  • Investments
Photo credits: pixabay.com

The ECB is following the lead of the FED. Although some council members warned not to ignore the risk of too high inflation, an end to the ultra-loose monetary policy is not in sight. Only the purchase of government and corporate securities under the Corona emergency purchase program should be "moderately" lower in the fourth quarter. The pro-growth decision is a balm for the stock markets. New highs should follow after the last mini-corrections.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: GAMESTOP CORP. A | US36467W1099 , WALLSTREET:ONLINE INH ON | DE000A2GS609 , NIKOLA CORP. | US6541101050

Table of contents:


    wallstreet:online - Pure growth

    The transformation into a financial services provider with an integrated community continues unabated, as already shown by the preliminary, unaudited figures for the first half of 2021. According to these figures, the Group increased its revenue by around 57% year-on-year to EUR 23.8 million in the first six months. Operating EBITDA before new customer acquisition costs for the Smartbroker rose to EUR 9.0 million, as expected, and almost doubled compared to the first half of 2020 when this stood at EUR 4.4 million. Operating EBITDA does not include customer acquisition costs for the Smartbroker, which amounted to just under EUR 8 million.

    Smartbroker's key growth figure, assets under management, rose to EUR 6.8 billion in the first six months, a threefold increase on the same period last year. These are in over 187,000 custody accounts, of which over 142,000 are customers of Smartbroker. The goal remains to open 200,000 accounts by the end of the year. Although growth weakened somewhat after the exceptional first quarter, also driven by meme shares, the already pronounced revenue forecast of between EUR 45-50 million is to be maintained. That makes the Smartbroker number one in terms of customer deposits and the clear number two among German neobrokers in terms of customer numbers.

    Particularly noteworthy is the fact that all areas of the Group contributed to growth. The reach of the financial portals averaged 376 million page impressions per month and increased by 37% year-on-year.

    The market capitalization of the wallstreet:online Group is currently EUR 345.80 million. The neobroker Trade Republic, which the Berliners were already able to leave behind in terms of assets under management, brings it to an incredible EUR 5 billion. So there is still a lot of catch-up potential here.

    Nikola - A new bride

    Initially, a financial investment by General Motors in truck manufacturer Nikola was planned last year. However, after the allegations of fraud, General Motors distanced itself visibly. Now Nikola presented a new strategic partner in the form of German automotive supplier Bosch. The US Company announced in a press release it will purchase key components such as the fuel cell stack, the compressor, the power electronics and the control unit with sensors from Bosch as part of a strategic agreement. These will then be assembled into fuel cell power modules at Nikola's US plant in Arizona. The first application is said to be planned in the US version of the Nikola Tre FCEV.

    Speculative investors could now get their money's worth with Nikola. After bottoming out in the EUR 9 area, the share has recovered to over EUR 11.45 in recent weeks. Exceeding the mark could generate price potential initially in the first target area at EUR 14.

    GameStop - Analysts disappointed

    Everyone knows the share of GameStop, at least since the meme hype when small investors in Reddit forums agreed to shoot the share "to the moon" to hurt hedge funds who bet on falling prices. The US video game retailer released its second-quarter numbers, which were encouraging thanks to a rebound in trading after the Corona lockdowns.

    Revenue increased by just over a quarter year-on-year to USD 1.18 billion. GameStop narrowed its loss from USD 111.3 million to USD 61.6 million. However, the Company was well below the estimates of analysts. An investment is still not pressing due to the astronomically high market capitalization of USD 12.93 billion.


    Monetary policy remains loose, and interest rates are historically low. As a result, the way is clear for growth and further rising capital markets. wallstreet:online is clearly undervalued compared to its neobroker competitors. Nikola is a speculative trading idea, and GameStop is not a serious investment at the current valuation.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read